<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
    </SeriesInfo>
    <SeriesHeader>
      <EditorGroup>
        <Editor AffiliationIDS="Aff1">
          <EditorName DisplayOrder="Western">
            <GivenName>J.M.</GivenName>
            <FamilyName>Walker</FamilyName>
          </EditorName>
        </Editor>
        <Affiliation ID="Aff1">
          <OrgName>School of Life Sciences University of Hertfordshire</OrgName>
          <OrgAddress>
            <City>Hatfield</City>
            <State>Hertfordshire, AL10 9AB</State>
            <Country>UK</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </SeriesHeader>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
        <BookID>978-1-60327-527-9</BookID>
        <BookTitle>T Cell Protocols</BookTitle>
        <BookSubTitle>Second Edition</BookSubTitle>
        <BookVolumeNumber>514</BookVolumeNumber>
        <BookSequenceNumber>514</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-527-9</BookDOI>
        <BookTitleID>145011</BookTitleID>
        <BookPrintISBN>978-1-58829-587-3</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-527-9</BookElectronicISBN>
        <BookChapterCount>11</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="SCL" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="SCL14005" Priority="1" Type="Secondary">Biochemistry, general</BookSubject>
          <BookSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</BookSubject>
          <BookSubject Code="SCL16020" Priority="3" Type="Secondary">Cell Culture</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor AffiliationIDS="Aff2">
            <EditorName DisplayOrder="Western">
              <GivenName>Gennaro</GivenName>
              <Particle>De</Particle>
              <FamilyName>Libero</FamilyName>
            </EditorName>
            <Role>Dr</Role>
            <Contact>
              <Email>Gennaro.DeLibero@unibas.ch</Email>
            </Contact>
          </Editor>
          <Affiliation ID="Aff2">
            <OrgName>University of Basel</OrgName>
            <OrgAddress>
              <State>Basel</State>
              <Country>Switzerland</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Chapter ID="Chap3" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
          <ChapterID>3</ChapterID>
          <ChapterNumber>Chapter 3</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-527-9_3</ChapterDOI>
          <ChapterSequenceNumber>3</ChapterSequenceNumber>
          <ChapterTitle Language="En">
            <Emphasis Type="Italic">transkingdom</Emphasis> RNA Interference (<Emphasis Type="Italic">tk</Emphasis>RNAi): A Novel Method to Induce Therapeutic Gene Silencing</ChapterTitle>
          <ChapterFirstPage>27</ChapterFirstPage>
          <ChapterLastPage>34</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2009</CopyrightYear>
          </ChapterCopyright>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-527-9</BookID>
            <BookTitle>T Cell Protocols</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Thu</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Nguyen</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Johannes</GivenName>
                <GivenName>H.</GivenName>
                <FamilyName>Fruehauf</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff3">
              <OrgDivision>Harvard Medical School</OrgDivision>
              <OrgName>Gl Cancer Laboratory, Division of Gastroenterology, Beth Israel Deaconess Medical Center</OrgName>
              <OrgAddress>
                <City>Boston</City>
                <State>MA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1" Language="En">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">RNA interference is a phenomenon in which specific, endogenous genes are silenced by mRNA degradation. This technology is highly regarded as a potential therapeutic due to its high efficacy and low toxicity. However, the difficulty of delivering RNAi to target cells has impeded the development of RNAi-based therapies. One method to overcome this barrier is the use of a nonpathogenic bacteria vector, <Emphasis Type="Italic">Escherichia coli</Emphasis>, to deliver RNAi to target cells with high efficacy. In <Emphasis Type="Italic">transkingdom</Emphasis> interference RNAi (<Emphasis Type="Italic">tk</Emphasis>RNAi) delivery, <Emphasis Type="Italic">E. coli</Emphasis> were engineered to transcribe short RNA (shRNA) from a plasmid (TRIP) containing the invasin gene <Emphasis Type="Italic">Inv</Emphasis> and the listeriolysin O gene <Emphasis Type="Italic">Hly.</Emphasis>
              <Emphasis Type="Italic">tk</Emphasis>RNAi is successful in eliciting efficient gene silencing in vitro and in vivo.</Para>
          </Abstract>
          <KeywordGroup Language="En">
            <Heading>Key words</Heading>
            <Keyword>RNAi</Keyword>
            <Keyword>
              <Emphasis Type="Italic">transkingdom</Emphasis> RNA interference</Keyword>
            <Keyword>
              <Emphasis Type="Italic">tk</Emphasis>RNAi</Keyword>
            <Keyword>shRNA</Keyword>
            <Keyword>siRNA</Keyword>
            <Keyword>Gene therapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" OutputMedium="Online" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">RNA interference (RNAi) is a naturally occurring pathway in which fragments of double-stranded ribonucleic acid (dsRNA) or short interference RNA (siRNA) selectively downregulate genes with complementary sequences to the siRNA <CitationRef CitationID="CR1">(1)</CitationRef>. The ability of RNAi to silence genes by degrading the mRNA and preventing protein expression has many advantageous implications for the field of biology. In addition to serving as a valuable genomic tool for the assessment of gene functions, RNAi can also be used as a means of genetic therapy to combat various diseases such as viral infections, cancer, and neurodegenerative disorders. While this innovative technology holds many promises for the future, the expansion of RNAi-based therapies is hindered by the challenge of delivering RNAi to target cells. Although the use of viral vectors, selective particles, liposomes, and chemical modifications to siRNA has been explored in the delivery of RNAi, little is known about the use of bacteria to induce gene silencing. Yet, as a versatile gene vector, <Emphasis Type="Italic">transkingdom</Emphasis> RNAi has recently been shown to be an effective, safe, and inexpensive measure for delivering RNAi to target cells with high selectivity and high specificity <CitationRef CitationID="CR2">(2</CitationRef>–<CitationRef CitationID="CR5">5)</CitationRef>.</Para>
            <Para TextBreak="No">The new bacteria-mediated RNAi delivery system termed <Emphasis Type="Italic">transkingdom</Emphasis> RNA interference (<Emphasis Type="Italic">tk</Emphasis>RNAi) combines production and delivery of short hairpin RNA in genetically modified bacteria, e.g., <Emphasis Type="Italic">E. coli.</Emphasis> Through the presence of the <Emphasis Type="Italic">transkingdom</Emphasis> RNA interference plasmid (TRIP) (<Emphasis Type="Bold">Fig.</Emphasis>
              <InternalRef RefID="Fig3_1_978-1-60327-527-9">3.1</InternalRef>), <Emphasis Type="Italic">E. coli</Emphasis> are enabled to produce specific shRNA, invade target cells, and release shRNA into the target cell cytoplasm, where they will trigger RNA interference. The TRIP plasmid contains three key components, the shRNA expression cassette, an <Emphasis Type="Italic">invasin</Emphasis> gene and a <Emphasis Type="Italic">listerolysin</Emphasis> gene, in addition to its bacterial origin and a selection marker.
<Figure Category="Standard" Float="Yes" ID="Fig3_1_978-1-60327-527-9">
                <Caption Language="En">
                  <CaptionNumber>Fig. 3.1.</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Structure of <Emphasis Type="Italic">transkingdom</Emphasis> RNA interference plasmid (TRIP).</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject>
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_3_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">The shRNA expression cassette allows for a high-level production of shRNA under the control of a T7 RNA polymerase promoter, and is flanked by two unique restriction sites, which give convenient access to change the shRNA expression insert. This enables the user to rapidly make numerous constructs targeting different genes of interest.</Para>
            <Para TextBreak="No">The introduction of the <Emphasis Type="Italic">inv</Emphasis> gene from <Emphasis Type="Italic">Yersinia pseudotuberculosis</Emphasis> leads to the expression of invasin protein on the bacterial surface and gives the <Emphasis Type="Italic">E. coli</Emphasis> the ability to invade beta(1)integrin expressing mammalian cells with high efficiency <CitationRef CitationID="CR4">(4)</CitationRef>. TRIP also encodes for the production of listeriolysin O, a pore-forming toxin (encoded by the <Emphasis Type="Italic">hly</Emphasis> gene from <Emphasis Type="Italic">Listeria monocytogenes)</Emphasis> in the bacterial cytoplasm, which leads to the destruction of the endosome membrane after bacterial uptake into the host cell <CitationRef CitationID="CR5">(5</CitationRef>–<CitationRef CitationID="CR7">7)</CitationRef>. After mammalian cell invasion, bacteria will reside in an endo/lysosome and lyse either due to their lack of intracellular survival mechanisms, the addition of antibiotics, or the action of lysosomes. At this time, listeriolysin as well as shRNA will be released, and listeriolysin will destroy the endosome membrane, allowing the shRNA to escape into the host cell cytoplasm, where it becomes processed into siRNA, a mediator of the RNAi pathway.</Para>
            <Para TextBreak="No">To illustrate the effects of this technology, a bacterial plasmid termed TRIP (<Emphasis Type="Italic">transkingdom</Emphasis> RNAi plasmid) was constructed against the human cancer gene <Emphasis Type="Italic">CTNNB1</Emphasis> (catenin β-1) and introduced into BL21DE3, a competent strain of nonpathogenic <Emphasis Type="Italic">E. coli</Emphasis>. The transformed strain of BL21DE3 was used to treat SW480 cells (human colon cancer) in vitro. <Emphasis Type="Italic">transkingdom</Emphasis> RNAi is also effective in inducing local and systemic gene silencing after application in live animals. <Emphasis Type="Italic">E. coli</Emphasis> expressing shRNA against mouse <Emphasis Type="Italic">Ctnnb1</Emphasis> was administered orally to induce local gene silencing in the intestinal epithelium of mice. After intravenous administration of <Emphasis Type="Italic">E. coli</Emphasis> encoding shRNA against human <Emphasis Type="Italic">CTNNB1</Emphasis> in mice with xenografts of human colon cancer, catenin levels were decreased in the tumors on mRNA and protein levels, and tumor growth was inhibited <CitationRef CitationID="CR2">(2)</CitationRef>.</Para>
          </Section1>
          <Section1 ID="Sec2" OutputMedium="Online">
            <Heading>Materials</Heading>
            <Section2 ID="Sec3" OutputMedium="Online">
              <Heading>Trip Plasmid Construction</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Emphasis Type="Italic">E. coli</Emphasis> strain BL21DE3.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Oligonucleotides containing multiple cloning sites, T7 promoter, enhancer and terminator (Qiagen).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Emphasis Type="Italic">CTNNB1</Emphasis> hairpin oligonucleotides.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Emphasis Type="Italic">Inv</Emphasis> gene and <Emphasis Type="Italic">Hly</Emphasis> gene sequences.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Pfx DNA polymerase (Invitrogen).</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec4" OutputMedium="Online">
              <Heading>Transformation of BL21DE3</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Competent BL21DE3 from Gene Therapy Systems.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec5" OutputMedium="Online">
              <Heading>
                <Emphasis Type="Italic">In Vitro</Emphasis> Transfection of SW480 Cells</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Brain–Heart-Infusion broth (Remel).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Ampicillin.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">IPTG.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">SW480 cells (human colon cancer cells).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RPMI1640 Medium (Sigma Aldrich).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Fetal Bovine Serum (Sigma Aldrich).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibiotics – Penicillin G, Streptomycin, and Amphotericin (Sigma Aldrich).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Ofloxacin (Sigma).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Cell culture dishes (6 cm).</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec6" OutputMedium="Online">
              <Heading>
                <Emphasis Type="Italic">In Vivo</Emphasis> Treatment</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Female C57/BL6 mice (Charles River Laboratories).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Female BALB/c nude mice (Charles River Laboratories).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Phosphate buffered saline (PBS)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec7" OutputMedium="Online">
              <Heading>Gene Silencing Analysis</Heading>
              <Section3 ID="Sec8" OutputMedium="Online">
                <Heading>RTq-PCR</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Taqman RTq-PCR primers for human <Emphasis Type="Italic">CTNNB1</Emphasis>
                          <OrderedList>
                            <ListItem>
                              <ItemNumber>1</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">hCTNNB1 reverse: 5’ – GGACAAAGGGCAAGATTT – 3’.</Para>
                              </ItemContent>
                            </ListItem>
                            <ListItem>
                              <ItemNumber>2</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">hCTNNB1 forward: 5’ – AGCTCTTACACCCACCATC – 3’</Para>
                              </ItemContent>
                            </ListItem>
                            <ListItem>
                              <ItemNumber>3</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">hCTNNB1 probe: 5’ – FAM-CTGGCCTCTGATAAAGGC – 3’.</Para>
                              </ItemContent>
                            </ListItem>
                          </OrderedList>
                        </Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Taqman RTq-PCR primers for mouse Ctnnb1<OrderedList>
                            <ListItem>
                              <ItemNumber>1</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">mbCAT reverse: 5’ – FAM –TCACGCAAGAGCAAGTAG – 3’.</Para>
                              </ItemContent>
                            </ListItem>
                            <ListItem>
                              <ItemNumber>2</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">mbCAT forward: 5’ – GAGCCCTAGTCATTGCATA – 3’.</Para>
                              </ItemContent>
                            </ListItem>
                            <ListItem>
                              <ItemNumber>3</ItemNumber>
                              <ItemContent>
                                <Para TextBreak="No">mbCAT probe: 5’ – FAM-TCACGCAAGAGCAAGTAG – 3’.</Para>
                              </ItemContent>
                            </ListItem>
                          </OrderedList>
                        </Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec9" OutputMedium="Online">
                <Heading>Immunohistochemistry</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Primary antibodies: Rabbit polyclonal β-catenin (1:250) (Santa Cruz).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">ABC (Vector) staining kit.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec10" OutputMedium="Online">
                <Heading>Northern Blot Analysis</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Antisense strand probe: 5’ – GUAGCUGAUAUUGAUGGACAG – 3’.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec11" OutputMedium="Online">
                <Heading>Western Blot Analysis</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Primary antibodies: Rabbit polyclonal В-catenin (1:500) (Santa Cruz).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Secondary antibodies: Goat anti-rabbit (1:100) (Santa Cruz).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec12" OutputMedium="Online">
            <Heading>Methods</Heading>
            <Para TextBreak="No">The following methods describe (1) the construction of the TRIP plasmid, (2) transformation of TRIP into <Emphasis Type="Italic">E. coli</Emphasis> bacteria, (3) in vitro treatment of SW480 cells, and (4) in vivo experiments involving oral treatment to induce gene silencing in intestinal epithelial cells and systemic dosing with intravenous treatment.</Para>
            <Section2 ID="Sec13" OutputMedium="Online">
              <Heading>TRIP Plasmid Construction</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Oligonucleotides containing multiple cloning site (MCS), T7 promoter, enhancer, and terminator (synthesized by Qiagen) were ligated into blunted <Emphasis Type="Italic">Bss</Emphasis>HII sites of KSII(+).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">shRNA encoding sequence (<Emphasis Type="Italic">CTNNB1</Emphasis> hairpin oligonucleotides) was inserted into the <Emphasis Type="Italic">Bam</Emphasis>HI and <Emphasis Type="Italic">SAl</Emphasis>I sites of the KSII(+) produce plasmid pT7RNAi against <Emphasis Type="Italic">CTNNB1</Emphasis>.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Emphasis Type="Italic">hly</Emphasis> gene was amplified from pGBΩ2<Emphasis Type="Italic">inv-hly</Emphasis> (kindly provided by C. Grillot-Courvalin) by PCR (Pfx DNA polymerase from Invitrogen) and with the use of hly-1 primer (5’-CCCTCCTTTGATT AGTATATTCCTATCTTA-3’) and hly-2 primer (5’-AAGCTTTTAAATCAGCAGGGGTCTTTTTGG-3’), and cloned into the <Emphasis Type="Italic">Eco</Emphasis>RV site of KSII(+) to make KSII(+)/<Emphasis Type="Italic">hly</Emphasis>.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The <Emphasis Type="Italic">Pst</Emphasis>I fragment containing the <Emphasis Type="Italic">inv</Emphasis> locus of pGBΩ2<Emphasis Type="Italic">inv-hly</Emphasis> was inserted into the <Emphasis Type="Italic">Pst</Emphasis>I site of KSII(+)/<Emphasis Type="Italic">hly.</Emphasis>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The <Emphasis Type="Italic">hly-Inv</Emphasis> fragment was excised with <Emphasis Type="Italic">Bam</Emphasis>HI and <Emphasis Type="Italic">Sal</Emphasis>I and blunted.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The blunted <Emphasis Type="Italic">Hly-Inv</Emphasis> fragment was ligated into the EcoRV site in the T7 terminator of the pT7RNAi to make TRIP (<Emphasis Type="Italic">see</Emphasis>
                        <Emphasis Type="Bold">Note</Emphasis>
                        <Emphasis Type="Bold">1</Emphasis>).</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec14" OutputMedium="Online">
              <Heading>Transformation of BL21DE3</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Transform TRIP plasmid into BL21DE3 strain using standard heat shock protocol.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec15" OutputMedium="Online">
              <Heading>
                <Emphasis Type="Italic">In Vitro</Emphasis> tkRNAi Treatment of SW480 Cells</Heading>
              <Section3 ID="Sec16" OutputMedium="Online">
                <Heading>Bacterial Culture</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Plate cells on agar plates containing 100 µg/ml ampicillin and incubate overnight at 37°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Select one colony and grow overnight in Brain–Heart-Infusion-broth (Remel) with 100 μg/ml ampicillin at 37°C, the night before cell transfection.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Inoculate overnight cultures of bacteria into fresh medium and grow for 2 h for effective transfection..</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Add IPTG (isopropyl-B-D-thio-galactopyranoside), an activator of T7 RNA polymerase, and incubate for an additional 1–2 h.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Measure bacteria count at OD<Subscript>600</Subscript> with a spectrophotometer (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note</Emphasis>
                          <Emphasis Type="Bold">2</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec17" OutputMedium="Online">
                <Heading>Cell Culture and Treatment Protocol for tkRNAi</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Culture SW480 cells into 6-cm plates at 30% confluence 18 h prior to treatment with bacteria.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Culture SW480 cells in RPMI1640 medium supplemented with antibiotics (100 U/ml penicillin G, 10 μg/ml streptomycin, and 2.5 μg/ml amphotericin) and 10% fetal bovine serum or FBS (Sigma).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Thirty minutes before the addition of bacteria for cell transfection, remove the old medium supplemented with FBS and antibiotics and replace with fresh medium without serum or antibiotics.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Meanwhile, spin down the bacteria while in early log phase at approximately 3,000 rpm for 10–15 min or until the bacteria has compacted into a pellet. Remove BHI medium, wash the bacteria in PBS, dilute in RPMI medium without serum and antibiotics and add to cells at the desired multiplicities of infection or MOIs.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Incubate cells with <Emphasis Type="Italic">E. coli</Emphasis> at varying MOIs for 1–2 h.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash cells extensively and treat with antibiotics to remove intracellular and extracellular bacteria (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note</Emphasis>
                          <Emphasis Type="Bold">3</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Culture cells for an additional 24–96 h before harvesting.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>8.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Analyze gene silencing.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>9.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Include appropriate controls (untreated and vector treated).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec18" OutputMedium="Online">
              <Heading>
                <Emphasis Type="Italic">In Vivo</Emphasis> Treatments with tkRNAi</Heading>
              <Section3 ID="Sec19" OutputMedium="Online">
                <Heading>Oral Treatment for Local Silencing</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Randomize female C57/BL6 mice into required groups, include appropriate controls (vehicle control, PBS control)</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Orally administer the treatment group with <Emphasis Type="Italic">E. coli</Emphasis> expressing shRNA against mouse <Emphasis Type="Italic">Ctnnb1</Emphasis> re-diluted in PBS.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Orally administer the vehicle control group with <Emphasis Type="Italic">E. coli</Emphasis> containing the TRIP vector against a control gene (e.g., GFP).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Treat both groups daily (up to 5 days per week) for the desired period (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Notes 4</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec20" OutputMedium="Online">
                <Heading>Treatment of Xenograft Tumors Through iv Treatment with tkRNAi</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Subcutaneous implantation of SW480 cells into the flank regions of female BALB/c nude mice approx 10 days prior to treatment. Randomize mice into appropriate treatment groups. Include appropriate controls (at least vector control, untreated control)</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Intravenous injections (tail vein injection) of the treatment group with 10<Superscript>6</Superscript> cfu <Emphasis Type="Italic">E. coli</Emphasis> expressing shRNA against <Emphasis Type="Italic">CTNNB1</Emphasis> re-diluted in 200 µl PBS</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Intravenous injections of the vector control group with <Emphasis Type="Italic">E. coli</Emphasis> containing the TRIP vector against a control gene (e.g., GFP).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Treat both groups three times per week for 3 weeks.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec21" OutputMedium="Online">
              <Heading>Analysis</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RTqPCR to quantify and determine changes in the levels of target gene RNA.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Western blot to determine target gene (and downstream) protein concentration.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Northern blot for detection and analysis of shRNA.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Immunohistochemistry staining to determine the distribution and localization of specific biomarkers.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec22" OutputMedium="Online">
            <Heading>Notes</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Activation of the <Emphasis Type="Italic">CTNNB1</Emphasis> cancer gene by means of overexpression or random mutations can lead to the development of a number of cancers, especially colon cancer. This pathway is widely targeted in experiments pertaining to the development of novel RNAi techniques since this cancer gene is often stabilized in cells. In terms of the TRIP plasmid, the production of shRNA is controlled by the bacteriophage T7 promoter and not by the promoter or enhancer of host mammalian cells. Furthermore, T7 RNA polymerase is provided by BL21DE3 to transcribe shRNA from TRIP. The <Emphasis Type="Italic">Inv</Emphasis> locus of the TRIP vector plays a key role in the admission of noninvasive <Emphasis Type="Italic">E. coli</Emphasis> into the β-1 integrin positive mammalian cells while the product of the <Emphasis Type="Italic">Hly</Emphasis> gene (listeriolysin O) initiates the release of genetic materials from vesicles <CitationRef CitationID="CR1">(1)</CitationRef>.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">It is recommended that one colony of bacteria is grown overnight in a 5 mL volume of BHI medium with ampicillin at 50–100 μg/ml. For optimal bacteria growth, 1% of the overnight culture should be inoculated, under sterile conditions, into a desired volume of BHI medium containing ampicillin and shaken for approximately 2 h at 37°C. After 2 h, add IPTG to the bacteria culture to maximize the transcription rate and incubate at 37°C for an additional 1–2 h. Best efficacies were observed with bacteria measured in the OD<Subscript>600</Subscript> range of 0.8–1.1 than at other ODs.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">For optimal transfection with <Emphasis Type="Italic">E. coli</Emphasis> while ensuring maximum cell survival rate, cells should be washed approximately 2–3 times with PBS and 2–3 times with complete medium (RPMI1640 medium containing serum and antibiotics) following the bacterial infection. Gene silencing potency increased with incubation times up to 2 h. Following the washes, add fresh, complete medium and Ofloxacin at 10 μg/ml. The potency of gene silencing is dependent on MOI, with near-complete gene silencing observed at an MOI of 1:1,000.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>4.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">A dosage of approximately 10<Superscript>9</Superscript>–10<Superscript>10</Superscript> colony-forming units (c.f.u.) is usually well tolerated for oral application. Treatment schedules can be optimized by monitoring bacterial shedding in the stools. Good treatment effects have been observed with the number of TRIP-carrying bacteria in the stools in the order of 5% and greater (this may allow to reduce the frequency of treatment).</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-527-9_Chapter_3.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Fire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK.</Initials>
                  <FamilyName>Montgomery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA.</Initials>
                  <FamilyName>Kostas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE.</Initials>
                  <FamilyName>Driver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC.</Initials>
                  <FamilyName>Mello</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Potent specific genetic interference by double-stranded RNA in <Emphasis Type="Italic">Caenorhabditis elegans</Emphasis>
                </ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>391</VolumeID>
                <FirstPage>806</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhtlCju74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/35888</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9486653</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent specific genetic interference by double-stranded RNA in <Emphasis Type="Italic">Caenorhabditis elegans</Emphasis>. Nature 1998;391:806–11</BibUnstructured>
            </Citation>
            <Citation ID="CR2">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Xiang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH.</Initials>
                  <FamilyName>Fruehauf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ.</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Short hairpin RNA-expressing bacteria elicit RNA interference in mammals</ArticleTitle>
                <JournalTitle>Nature Biotechnology</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>697</FirstPage>
                <LastPage>702</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XlsVequ7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nbt1211</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16699500</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xiang S, Fruehauf JH, Li CJ. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nature Biotechnology 2006;4:697–702.</BibUnstructured>
            </Citation>
            <Citation ID="CR3">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CX.</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E.</Initials>
                  <FamilyName>Menocal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Xiang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Borodyansky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH.</Initials>
                  <FamilyName>Fruehauf</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Delivery of RNA interference</ArticleTitle>
                <JournalTitle>Cell Cycle</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>2103</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtlGqsrzP</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.4161/cc.5.18.3192</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16940756</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006;5:2103–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RR.</Initials>
                  <FamilyName>Isberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM.</Initials>
                  <FamilyName>Leong</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>861</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXhvFKjtb4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0092-8674(90)90099-Z</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>2311122</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Isberg RR, Leong JM. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 1990;60:861–71</BibUnstructured>
            </Citation>
            <Citation ID="CR5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R.</Initials>
                  <FamilyName>Palffy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R.</Initials>
                  <FamilyName>Gardlik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J.</Initials>
                  <FamilyName>Hodosy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Bacteria in gene therapy: bactofection versus alternative gene therapy</ArticleTitle>
                <JournalTitle>Gene Therapy</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>5</LastPage>
              </BibArticle>
              <BibUnstructured>Palffy R, Gardlik R, Hodosy J, et al. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Therapy 2005;10:1–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR6">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C.</Initials>
                  <FamilyName>Grillot-Courvalin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Groussard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F.</Initials>
                  <FamilyName>Huetz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM.</Initials>
                  <FamilyName>Ojcius</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Courvalin</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Functional gene transfer from intracellular bacteria to mammalian cells</ArticleTitle>
                <JournalTitle>Nature Biotechnology</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>862</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlvFWkur8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nbt0998-862</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9743121</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grillot-Courvalin C, Groussard S, Huetz F, Ojcius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nature Biotechnology 1998;16:862–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR7">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ.</Initials>
                  <FamilyName>Wing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH.</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">
                  <Emphasis Type="Italic">Listeria monocytogenes</Emphasis>: Clinical and experimental update</ArticleTitle>
                <JournalTitle>Journal of Infectious Diseases</JournalTitle>
                <VolumeID>185</VolumeID>
                <FirstPage>18</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1086/338465</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wing EJ, Gregory SH. <Emphasis Type="Italic">Listeria monocytogenes</Emphasis>: Clinical and experimental update. Journal of Infectious Diseases 2002;185:18–24.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Book>
  </Series>
</Publisher>
